EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions

Tianen Chen, Suparat Tongpeng, Ziyi Lu, Win Topatana, Sarun Juengpanich, Shijie Li, Jiahao Hu, Jiasheng Cao, Cheeshin Lee, Yitong Tian, Mingyu Chen, Xiujun Cai

Aging and Cancer · 2022-03 · 3 (1) · 44-67

DOI: 10.1002/aac2.12047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging and Cancer, online erschienen am 07.03.2022. Verfasst von Tianen Chen und 11 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA molecules are subject to various lesions that can be detrimental to the cells. DNA damage response (DDR) pathways encompass a variety of mechanisms that cells employ in response to DNA damage. While DDR promotes genomic stability in normal cells, it also protects cancer cells from DNA lesions, particularly against exogenous DNA‐damaging agents. Therefore, DDR pathways can be exploited to account for resistance to chemotherapy and radiotherapy and have the potential to be targeted in cancer treatment. Apart from the poly (ADP‐ribose) polymerase (PARP) inhibitors used in BRCA‐mutant cancers, other DDR inhibitors are being developed and tested in clinical trials. Based on the synthetic lethality theory, combination therapies utilizing DDR inhibitors have been explored and are currently undergoing clinical trials, with promising results in cancer treatment. Combination therapies typically employ a DDR inhibitor to sensitize cancer cells to traditional chemotherapeutic agents, radiotherapy, immunotherapy, and even PARP inhibitors. Herein, we focus on recent advances in DDR inhibitor‐based combination therapies other than PARP inhibitors, explore the advantages and disadvantages of the strategies, and discuss the current challenges and future perspectives.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, T., Tongpeng, S., Lu, Z., Topatana, W., Juengpanich, S., Li, S., Hu, J., Cao, J., Lee, C., Tian, Y., Chen, M., & Cai, X. (2022). DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions. Aging and Cancer, 3(1), 44-67. https://doi.org/10.1002/aac2.12047

Vancouver

Chen T, Tongpeng S, Lu Z, Topatana W, Juengpanich S, Li S, et al. DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions. Aging and Cancer. 2022;3(1):44-67. doi:10.1002/aac2.12047

BibTeX
@article{Chen2022,
  author = {Chen, Tianen and Tongpeng, Suparat and Lu, Ziyi and Topatana, Win and Juengpanich, Sarun and Li, Shijie and Hu, Jiahao and Cao, Jiasheng and Lee, Cheeshin and Tian, Yitong and Chen, Mingyu and Cai, Xiujun},
  title = {DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions},
  journal = {Aging and Cancer},
  year = {2022},
  volume = {3},
  number = {1},
  pages = {44--67},
  doi = {10.1002/aac2.12047}
}
Kostenlos starten →